Cargando…
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
microRNAs (miRNAs) play critical roles in cancer development and progression. This study investigated the effects of miR-138-5p in human colorectal cancer (CRC) development. miR-138-5p was frequently downregulated in CRC tissues and was associated with advanced clinical stage, lymph node metastasis...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216728/ https://www.ncbi.nlm.nih.gov/pubmed/27248318 http://dx.doi.org/10.18632/oncotarget.9659 |
_version_ | 1782491969303347200 |
---|---|
author | Zhao, Lian Yu, Haibo Yi, Shuijing Peng, Xiaowei Su, Peng Xiao, Zhiming Liu, Rui Tang, Anliu Li, Xiayu Liu, Fen Shen, Shourong |
author_facet | Zhao, Lian Yu, Haibo Yi, Shuijing Peng, Xiaowei Su, Peng Xiao, Zhiming Liu, Rui Tang, Anliu Li, Xiayu Liu, Fen Shen, Shourong |
author_sort | Zhao, Lian |
collection | PubMed |
description | microRNAs (miRNAs) play critical roles in cancer development and progression. This study investigated the effects of miR-138-5p in human colorectal cancer (CRC) development. miR-138-5p was frequently downregulated in CRC tissues and was associated with advanced clinical stage, lymph node metastasis and poor overall survival. We found that miR-138-5p decreased expression of programmed cell death ligand 1 (PD-L1) through interaction with its PD-L1 3′ untranslated region. miR-138-5p also dramatically suppressed CRC cell growth in vitro and inhibited tumorigenesis in vivo. PD-L1 and miR-138-5p levels were inversely correlated in human CRC tumors, and miR-138-5p inhibited PD-L1 expression in tumor models. These results suggest that miR-138-5p is a tumor suppressor in CRC, and its effects are exerted at least partially through PD-L1 downregulation. Low miR-138-5p and high PD-L1 levels correlated with shorter overall CRC patient survival, indicating that miR-138-5p and PD-L1 may serve as CRC biomarkers for risk group assignment, optimal therapy selection and clinical outcome prediction. Targeting PD-L1, possibly by administering miR-138-5p mimics, might be a clinically effective anti-CRC therapeutic strategy. |
format | Online Article Text |
id | pubmed-5216728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-52167282017-01-15 The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer Zhao, Lian Yu, Haibo Yi, Shuijing Peng, Xiaowei Su, Peng Xiao, Zhiming Liu, Rui Tang, Anliu Li, Xiayu Liu, Fen Shen, Shourong Oncotarget Research Paper microRNAs (miRNAs) play critical roles in cancer development and progression. This study investigated the effects of miR-138-5p in human colorectal cancer (CRC) development. miR-138-5p was frequently downregulated in CRC tissues and was associated with advanced clinical stage, lymph node metastasis and poor overall survival. We found that miR-138-5p decreased expression of programmed cell death ligand 1 (PD-L1) through interaction with its PD-L1 3′ untranslated region. miR-138-5p also dramatically suppressed CRC cell growth in vitro and inhibited tumorigenesis in vivo. PD-L1 and miR-138-5p levels were inversely correlated in human CRC tumors, and miR-138-5p inhibited PD-L1 expression in tumor models. These results suggest that miR-138-5p is a tumor suppressor in CRC, and its effects are exerted at least partially through PD-L1 downregulation. Low miR-138-5p and high PD-L1 levels correlated with shorter overall CRC patient survival, indicating that miR-138-5p and PD-L1 may serve as CRC biomarkers for risk group assignment, optimal therapy selection and clinical outcome prediction. Targeting PD-L1, possibly by administering miR-138-5p mimics, might be a clinically effective anti-CRC therapeutic strategy. Impact Journals LLC 2016-05-27 /pmc/articles/PMC5216728/ /pubmed/27248318 http://dx.doi.org/10.18632/oncotarget.9659 Text en Copyright: © 2016 Zhao et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Zhao, Lian Yu, Haibo Yi, Shuijing Peng, Xiaowei Su, Peng Xiao, Zhiming Liu, Rui Tang, Anliu Li, Xiayu Liu, Fen Shen, Shourong The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer |
title | The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer |
title_full | The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer |
title_fullStr | The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer |
title_full_unstemmed | The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer |
title_short | The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer |
title_sort | tumor suppressor mir-138-5p targets pd-l1 in colorectal cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216728/ https://www.ncbi.nlm.nih.gov/pubmed/27248318 http://dx.doi.org/10.18632/oncotarget.9659 |
work_keys_str_mv | AT zhaolian thetumorsuppressormir1385ptargetspdl1incolorectalcancer AT yuhaibo thetumorsuppressormir1385ptargetspdl1incolorectalcancer AT yishuijing thetumorsuppressormir1385ptargetspdl1incolorectalcancer AT pengxiaowei thetumorsuppressormir1385ptargetspdl1incolorectalcancer AT supeng thetumorsuppressormir1385ptargetspdl1incolorectalcancer AT xiaozhiming thetumorsuppressormir1385ptargetspdl1incolorectalcancer AT liurui thetumorsuppressormir1385ptargetspdl1incolorectalcancer AT tanganliu thetumorsuppressormir1385ptargetspdl1incolorectalcancer AT lixiayu thetumorsuppressormir1385ptargetspdl1incolorectalcancer AT liufen thetumorsuppressormir1385ptargetspdl1incolorectalcancer AT shenshourong thetumorsuppressormir1385ptargetspdl1incolorectalcancer AT zhaolian tumorsuppressormir1385ptargetspdl1incolorectalcancer AT yuhaibo tumorsuppressormir1385ptargetspdl1incolorectalcancer AT yishuijing tumorsuppressormir1385ptargetspdl1incolorectalcancer AT pengxiaowei tumorsuppressormir1385ptargetspdl1incolorectalcancer AT supeng tumorsuppressormir1385ptargetspdl1incolorectalcancer AT xiaozhiming tumorsuppressormir1385ptargetspdl1incolorectalcancer AT liurui tumorsuppressormir1385ptargetspdl1incolorectalcancer AT tanganliu tumorsuppressormir1385ptargetspdl1incolorectalcancer AT lixiayu tumorsuppressormir1385ptargetspdl1incolorectalcancer AT liufen tumorsuppressormir1385ptargetspdl1incolorectalcancer AT shenshourong tumorsuppressormir1385ptargetspdl1incolorectalcancer |